These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 2908949

  • 1. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF.
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [Abstract] [Full Text] [Related]

  • 2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [Abstract] [Full Text] [Related]

  • 3. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
    Bretton PR, Herr HW, Kimmel M, Fair WR, Whitmore WF, Melamed MR.
    J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
    [Abstract] [Full Text] [Related]

  • 4. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
    Badalament RA, Gay H, Cibas ES, Herr HW, Whitmore WF, Fair WR, Melamed MR.
    J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
    [Abstract] [Full Text] [Related]

  • 7. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR.
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [Abstract] [Full Text] [Related]

  • 8. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL.
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [Abstract] [Full Text] [Related]

  • 12. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL.
    J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
    [Abstract] [Full Text] [Related]

  • 15. Bladder cancer immunotherapy.
    Lamm DL, Thor DE, Stogdill VD, Radwin HM.
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [Abstract] [Full Text] [Related]

  • 16. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR.
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [Abstract] [Full Text] [Related]

  • 17. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS, Perry A.
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [Abstract] [Full Text] [Related]

  • 18. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR, Cundiff MR, Schellhammer PF.
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [Abstract] [Full Text] [Related]

  • 19. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB, Huang MY, Lindner A, Smith RB, Kaufman JJ.
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL.
    J Urol; 1988 May; 139(5):941-4. PubMed ID: 3361668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.